PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: PF-06410293
Drug: adalimumab

First Posted Date: 2020-01-18

Last Posted Date: 2024-02-22

Lead Sponsor: Pfizer

Target Recruit Count: 455

Registration Number: NCT04230213

Locations: 🇨🇿
Lekarna Pod Platany, Praha, Czechia
🇧🇬
Unimed Medical Centre, Plovdiv, Bulgaria
🇨🇿
L.K.N. Arthrocentrum, s.r.o., Hlucin, Czechia

and more 69 locations

Acute Myeloid Leukemia Real World Treatment Patterns

Withdrawn

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: azacitidine
Drug: venetoclax
Drug: glasdegib

First Posted Date: 2020-01-18

Last Posted Date: 2023-06-07

Lead Sponsor: Pfizer

Registration Number: NCT04230564

A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.

Phase 2

Terminated

Conditions: Lower Resp Tract Infection
Respiratory Syncytial Virus (RSV)

Interventions: Drug: RV521
Drug: Placebo

First Posted Date: 2020-01-13

Last Posted Date: 2024-10-23

Lead Sponsor: Pfizer

Target Recruit Count: 51

Registration Number: NCT04225897

Locations: 🇨🇷
Corporacion Gihema, San Jose, Costa Rica
🇨🇷
Hospital Metropolitano, Sede San Jose, San Jose, Costa Rica
🇲🇾
Hospital Seberang Jaya, Seberang Jaya, Pulau Pinang, Malaysia

and more 56 locations

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Voxelotor

First Posted Date: 2020-01-06

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 236

Registration Number: NCT04218084

Locations: 🇪🇬
Cairo University Hospital, Abu El Rish Hospital, Cairo, Egypt
🇪🇬
Abu Elrish Children Hospital, Cairo, Egypt
🇪🇬
Egyptian Thalassemia Association (satellite site), Cairo, Egypt

and more 49 locations

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Phase 2

Withdrawn

Conditions: Ulcerative Colitis

Interventions: Drug: PF-06826647 300 mg QD
Drug: Placebo
Drug: PF-06826647 100 mg QD
Drug: PF-06826647 600 mg QD
Drug: PF-6826647 400 mg QD

First Posted Date: 2019-12-24

Last Posted Date: 2020-12-17

Lead Sponsor: Pfizer

Registration Number: NCT04209556

Locations: 🇺🇸
ADVA Clinical Research, Inglewood, California, United States
🇺🇸
Hope Clinical Research, Canoga Park, California, United States
🇺🇸
Gastroenterology Consultants P.C., Roswell, Georgia, United States

and more 21 locations

The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Withdrawn

Conditions: Atrial Fibrillation

Interventions: Drug: apixaban
Drug: warfarin

First Posted Date: 2019-12-13

Last Posted Date: 2020-06-01

Lead Sponsor: Pfizer

Registration Number: NCT04198844

Locations: 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of

Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries

Completed

Conditions: Community Acquired Pneumonia
Complicated Skin and Soft Tissue Infection

Interventions: Drug: Zinforo (ceftaroline fosamil)

First Posted Date: 2019-12-13

Last Posted Date: 2024-03-26

Lead Sponsor: Pfizer

Target Recruit Count: 317

Registration Number: NCT04198571

Locations: 🇪🇸
Hospital Universitario Valle de Hebrón, Barcelona, Spain
🇪🇸
Hospital Ramon y Cajal, Madrid, Spain
🇨🇴
Centro médico Imbanaco, Cali, Colombia

and more 23 locations

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: PF-06835919 25 mg

First Posted Date: 2019-12-10

Last Posted Date: 2024-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT04193436

Locations: 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰
Summit Clinical Research, s.r.o.,, Bratislava, Slovakia
🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Open-Label Extension of Voxelotor

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor

First Posted Date: 2019-12-06

Last Posted Date: 2024-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 162

Registration Number: NCT04188509

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Healthcare of Atlanta Scottish Rite, Atlanta, Georgia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 19 locations

Safety and Efficacy of Trastuzumab BS

Active, not recruiting

Conditions: Gastric Cancer

Interventions: Drug: TRASTUZUMAB BS

First Posted Date: 2019-11-29

Last Posted Date: 2024-10-23

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT04181333

Locations: 🇯🇵
Pfizer, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy